Telotristat etiprate: Preliminary Phase II data

Preliminary data from a 12-week, open-label, dose-escalation, European Phase II trial showed that 5 of 6 evaluable patients with refractory carcinoid syndrome treated with thrice-daily LX1032 achieved...